Alzheimer’s Disease is one of the most prevalent neurodegenerative diseases causing insufferable pain to patients and their families. There are over 55 million people worldwide living with dementia, and Alzheimer’s Disease is the most common form of dementia. Unfortunately, the aging population will only exacerbate the prevalence of the disease, yielding immense medical costs in addition to the already devastating social burden. At BeauBrain Healthcare, we are revolutionizing the current treatment paradigm from “post-diagnosis treatment” to “pre-emptive intervention.” Our solutions enable early identification of the disease through predictive analysis of disease-specific biomarkers (Amyloid Beta, Tau, Neurodegeneration), and a personalized cognitive training platform (DTx). Ultimately, our long-term vision is to realize precision medicine for Alzheimer’s disease through the biomarker data generated from our diverse solutions combined with a vast amount of genetic data.
